Piyasa açık· · CHF · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
Ad-hoc announcement pursuant to Article 53 of the SIX listing rulesKuros Biosciences delivers 45% H1 2026 year-over-year sales growth and increases overall profitability Schlieren (Zurich), Switzerland, August 13, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced its financial and operational results for the first half of 2026.Financial HighlightsTotal Medical Device sales increased 45% to USD 92.4 million in H1 2026 (H1 20
Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich Schlieren (Zürich), Switzerland, June 17, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, is pleased to announce today’s Capital Markets Day on Wednesday, June 17, 2026, at 9am CEST, at the Mandarin Oriental Savoy, Zürich, Switzerland. The event will also be available virtually via live webcast. Capital Markets Day wil
As European markets navigate a period of uncertainty, marked by mixed economic signals and geopolitical tensions, investors are keenly observing growth companies that demonstrate resilience. In such an environment, stocks with high insider ownership can be particularly appealing as they often signal confidence from those closest to the company's operations and future prospects.
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.